



US009078923B2

(12) United States Patent
Dhuppad et al.**(10) Patent No.: US 9,078,923 B2****(45) Date of Patent: Jul. 14, 2015****(54) STABLE FIXED DOSE PHARMACEUTICAL
COMPOSITION COMPRISING
MOMETASONE AND OLOPATADINE**A61K 31/575; A61K 47/32; A61K 9/0048;
A61K 31/00; A61K 31/445

See application file for complete search history.

(71) Applicant: Glenmark Pharmaceuticals Limited,
Mumbai (IN)**(56) References Cited**

U.S. PATENT DOCUMENTS

(72) Inventors: Ulhas Dhuppad, Maharashtra (IN);
Ashok Katkurwar, Maharashtra (IN);
Yashwant Gupta, Maharashtra (IN);
Rajesh Ankam, Maharashtra (IN);
Chandrakant Dhatrak, Maharashtra
(IN)

4,871,865 A	10/1989	Lever, Jr. et al.	
4,923,892 A	5/1990	Lever, Jr. et al.	
5,837,699 A	11/1998	Sequeira et al.	
6,127,353 A	10/2000	Yuen et al.	
7,977,376 B2	7/2011	Singh et al.	
8,399,508 B2	3/2013	Singh et al.	
2004/0097474 A1	5/2004	Cagle et al.	
2006/0110328 A1 *	5/2006	Cagle et al.	424/45
2008/0058296 A1 *	3/2008	Chaudry	514/169
2012/0121653 A1 *	5/2012	Jenkins et al.	424/400

**(73) Assignee: GLENMARK PHARMACEUTICALS
LIMITED, Mumbai (IN)****(*) Notice:** Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

FOREIGN PATENT DOCUMENTS

(21) Appl. No.: 14/483,837

WO	WO-0126658	4/2001
WO	WO-2006057769 A2	6/2006
WO	WO-2009003199	12/2008
WO	WO-2010025236 A1	3/2010
WO	WO-2011141929 A2	11/2011
WO	WO-2012094283	7/2012
WO	WO-2014092346 A1	6/2014

(22) Filed: Sep. 11, 2014**(65) Prior Publication Data**

US 2015/0079178 A1 Mar. 19, 2015

Related U.S. Application Data**(63)** Continuation-in-part of application No. PCT/
IB2014/064251, filed on Sep. 4, 2014.**(30) Foreign Application Priority Data**

Sep. 13, 2013 (IN) 2975/MUM/2013

(51) Int. Cl.

A61P 27/14	(2006.01)
A61K 31/5513	(2006.01)
A61K 31/575	(2006.01)
A61K 31/355	(2006.01)
A61K 9/00	(2006.01)
A61K 31/573	(2006.01)
A61K 47/38	(2006.01)
A61K 31/58	(2006.01)
A61K 31/335	(2006.01)
A61K 47/36	(2006.01)
A61K 47/18	(2006.01)
A61K 47/26	(2006.01)
A61K 47/02	(2006.01)

(52) U.S. Cl.CPC **A61K 47/38** (2013.01); **A61K 9/0043**
(2013.01); **A61K 31/335** (2013.01); **A61K**
31/58 (2013.01); **A61K 47/02** (2013.01); **A61K**
47/186 (2013.01); **A61K 47/26** (2013.01);
A61K 47/36 (2013.01)**(58) Field of Classification Search**CPC . A61K 2300/00; A61K 31/335; A61K 31/14;
A61K 31/198; A61K 33/42; A61K 9/0043;
A61K 31/355; A61K 31/5513; A61K 31/573;Roland et al; Olopatadine nasal spray for the treatment of seasonal
allergic rhinitis in patients aged 6 years and older, Expert Opin
Pharmacother. 2010, 11(9), 1559-1567.Bajaj et al; Benefits of Skin Prick Tests for Allergic Rhinitis, The
internet Journal of Otorhinolaryngology, 2006, vol. 6, No. 1.Nsouli S, et al; Combination of a nasal antihistamine olopatadine and
a nasal corticosteroid, mometasone . . . , International Scientific
Conference, Dubai, UAE, Dec. 2010.Austin, et al; Mometasone Furoate is a less specific Glucocorticoid
than Fluticasone Propionate, European Respiratory Journal, 2002, 20,
1386-1392.Johnson, M., PhD; Development of Fluticasone Propionate and
Comparison with other Inhaled Corticosteroids, J Allergy Clin
Immunol, Apr. 1998, 101(4), Part 2, S434-S439.International Search Report, for International Application PCT/
IB2014/064251; dated Nov. 19, 2014, pp. 1-13.

* cited by examiner

Primary Examiner — Audrea Buckley*(74) Attorney, Agent, or Firm* — Blank Rome LLP**(57) ABSTRACT**The present invention relates to a stable fixed dose aqueous
pharmaceutical composition (e.g., contained in a container)
for nasal administration to a human, comprising mometasone
or its salt, olopatadine or its salt. The composition may further
include a hydrocolloid. The invention also relates to a process
for preparing the pharmaceutical composition, and the use of
the pharmaceutical composition in the treatment of rhinitis in
a subject.**21 Claims, No Drawings**